{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Prophylactic Inotropic Agents in Cardiac Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This randomised controlled trial involved individual participant randomisation."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were adults undergoing cardiac surgery without LCOS signs."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive inotropic agents or control (standard care, placebo, or other inotropes)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial assesses the prophylactic use of inotropic agents to prevent LCOS in adults undergoing cardiac surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was LCOS incidence within 48 hours post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 3307 participants were randomised: 1654 to the intervention and 1653 to the control group, recruited between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 1620 in the intervention and 1625 in the control group, using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Levosimendan reduced LCOS risk (RR 0.43, 95% CI 0.25 to 0.74) and mortality (RR 0.65, 95% CI 0.43 to 0.97)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with no significant differences in cardiogenic shock, atrial fibrillation, or myocardial infarction."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by [Funding Source]."
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}